MMJ PhytoTech
(ASX:MMJ) has announced Harvest One Cannabis, in which it holds a 59 per cent stake, has released an operation update on its business arm Satipharm.
Satipharm is the medical arm of Harvest One Cannabis, an umbrella company that controls operations across the entire cannabis value chain.
Key updates on the Satipharm business include the receipt of a German ‘Free Sales Certificate’, reducing constraints for international exports, and final approval from the Australian Regulatory Authority for CBD capsule prescription in Australia.
Other updates include a strong increase in European dietary supplement sales and new capsule formations including THC underway.
Shares in MMJ PhytoTech
(ASX:MMJ) last traded flat at $0.34 cents.
